Oncimmune’s lung clinical advisory group consists of senior scientists and physicians in lung cancer. This group advises the company on the key clinical considerations entailed in using our blood test for lung cancer.
Consultant Respiratory Physician, Nottingham University Hospitals, Honorary Professor, School of Medicine, University of Nottingham
Professor Peter Boyle, BSc PhD DSc (Med) DSc FRSE FFPH FRCPS (Glas) FRCP (Edin) FMedSci is President of the International Prevention Research Institute, Lyon, France and was previously Director of the International Agency for Research on Cancer (IARC/WHO) from 2004 to 2008 in Lyon, France. Professor Boyle is also currently Honorary Professor of Cancer Prevention and Control at Oxford University and Visiting Professor at Glasgow University.
Frank Detterbeck, MD, FACS, FCCP is a Professor of Surgery and Chief of Thoracic Surgery at Yale University and Associate Director of the Yale Cancer Center. He specializes in the surgical treatment of lung cancer, lung metastases, esophageal cancer, thymoma, mediastinal tumors, chest wall tumors, Pancoast tumors, mesothelioma, and sarcoma. The majority of his thoracic/chest surgeries are performed using minimally invasive techniques. His clinical research includes cancer biology, cancer imaging techniques, prognostic markers of cancers, multimodality (multiple therapies for) treatment of cancer, and evidence-based medicine.
Professor Herb Fritsche, PhD, MD received his BS degree in Chemistry from the University of Houston in 1963, a Masters degree (1965) and a PhD (1968) in Chemistry from Texas A & M University. He has sat on a number of committees of professional societies, been involved with several Scientific Advisory Boards and has numerous honours and awards. He has been Chief Science Officer of Health Discovery Corp. since September 2010. He has been appointed Senior Vice President and member of Board of Directors since July 2011. Prior to joining Health Discovery Corp. Dr. Fritsche was Professor of laboratory Medicine and Chief Chemistry Section at The University of Texas, MD Anderson Cancer Center in Houston, Texas. During his 41 years at MD Anderson Cancer Center, Dr. Fritsche focused his research activities on the development and validation of cancer diagnostics. His research activities included some of the earliest work in tumour markers, more recently, tests for circulating DNA, urine mRNA for bladder cancer detection and circulating tumour cell assays for establishing prognosis of patients with metastatic cancers.
Dr Jett’s research interests focus on the screening and early detection of lung cancer. His research has been funded by the National Cancer Institute and he was part of a research team that documented how CT screening can be an effective tool to detect lung cancer early in high-risk patients. Dr Jett is board certified in Internal Medicine and Pulmonary Medicine. He completed his medical degree at the University of Missouri, Columbia. He completed a residency in Internal Medicine and a fellowship in Pulmonary Diseases at Mayo Graduate School of Medicine, and a research fellowship at the National Cancer Institute. He is on the Scientific Advisory Committee for the American Lung Association and was an External Review Chair for the Terry Fox Research Institute, Lung Cancer Grant Review. Dr Jett has served in journal review for many medical publications, including the American Journal of Respiratory and Critical Care Medicine, Annals of Internal Medicine, Cancer, Chest, International Journal of Cancer, Lung Cancer and The New England Journal of Medicine. He has been on the Editorial Boards of CHEST, THORAX and American Journal of Respiratory and Critical Care Medicine Dr. Jett was editor-in-chief of the Journal of Thoracic Oncology from 2006 to 2012 and was Co-Editor from 2008-2017 of the Lung Cancer Section of the electronic textbook “Up-To-Date”.
Pulmonologist University of Colorado
Pulmonologist Vanderbilt, Nashville
Pulmonologist Cleveland Clinic
Dr Navani qualified in Medicine from Cambridge and UCL in 2000 with distinction and several University prizes. He trained in Respiratory Medicine at the Brompton and Hammersmith Hospitals before winning a Medical Research Council Fellowship in 2008 and completing his PhD at UCL in 2011. He has also completed an MSc in Clinical Trials at the London School of Hygiene and Tropical Medicine. Dr Navani is a Consultant in Thoracic Medicine at University College London Hospital. He specialises in respiratory disorders and has particular expertise in patients with lung cancer and in bronchoscopy. He runs the regional Endobronchial Ultrasound (EBUS) service at UCLH and has performed over 3,000 procedures. Dr Navani is clinical lead for lung cancer services at UCLH and co-chairs the specialist lung cancer weekly MDT.
Dr Navani runs several clinical trials on the diagnosis and staging of lung disease and bronchoscopic techniques. He holds an honorary position at the Medical Research Council Clinical Trials Unit and is also a member of the UCLH early lung cancer detection and surveillance programme. Dr Navani has authored over 35 peer-reviewed publications, including leading articles on endobronchial ultrasound. He is the co-author of a textbook on respiratory disorders. He is an invited member of the British Thoracic Society guideline development group for bronchoscopy and is on the interventional procedures specialist advisory group. He is a member of the National Cancer Research Institute lung cancer clinical studies group. He sits on the lung cancer board of London Cancer and is a peer reviewer for many journals including PLOSoneand Thorax.
Associate Professor of Medicine at the Hospital of the University of Pennsylvania and the Veteran’s Administration Medical Center
Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).
These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.
None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.
By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.